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Background: Adequately powered studies directly comparing hard clinical outcomes of darbepoetin alfa
(DPO) versus epoetin alfa (EPO) in patients undergoing dialysis are lacking.
Study Design: Observational, registry-based, retrospective cohort study; we mimicked a cluster-
randomized trial by comparing mortality and cardiovascular events in US patients initiating hemodialysis
therapy in facilities (almost) exclusively using DPO versus EPO.
Setting & Participants: Nonchain US hemodialysis facilities; each facility switching from EPO to DPO
(2003-2010) was matched for location, profit status, and facility type with one EPO facility. Patients subse-
quently initiating hemodialysis therapy in these facilities were assigned their facility-level exposure.
Intervention: DPO versus EPO.
Outcomes: All-cause mortality, cardiovascular mortality; composite of cardiovascular death, nonfatal
myocardial infarction (MI), and nonfatal stroke.
Measurements: Unadjusted and adjusted HRs from Cox proportional hazards regression models.
Results: Of 508 dialysis facilities that switched to DPO, 492 were matched with a similar EPO facility;
19,932 (DPO: 9,465 [47.5%]; EPO: 10,467 [52.5%]) incident hemodialysis patients were followed up for
21,918 person-years during which 5,550 deaths occurred. Almost all baseline characteristics were tightly
balanced. The demographics-adjusted mortality HR for DPO (vs EPO) was 1.06 (95% CI, 1.00-1.13) and
was materially unchanged after adjustment for all other baseline characteristics (HR, 1.05; 95% CI, 0.99-
1.12). Cardiovascular mortality did not differ between groups (HR, 1.05; 95% CI, 0.94-1.16). Nonfatal
outcomes were evaluated among 9,455 patients with fee-for-service Medicare: 4,542 (48.0%) in DPO and
4,913 (52.0%) in EPO facilities. During 10,457 and 10,363 person-years, 248 and 372 events were
recorded, respectively, for strokes and MIs. We found no differences in adjusted stroke or MI rates or their
composite with cardiovascular death (HR, 1.10; 95% CI, 0.96-1.25).
Limitations: Nonrandom treatment assignment, potential residual confounding.
Conclusions: In incident hemodialysis patients, mortality and cardiovascular event rates did not differ
between patients treated at facilities predominantly using DPO versus EPO.
Am J Kidney Dis. 66(1):106-113. ª 2015 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
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Darbepoetin Versus Epoetin in HemodialysisESA used by large dialysis chains, whereas the more
recently approved longer-acting ESA, darbepoetin alfa
(DPO), is mainly used in independent and hospital-
based dialysis units.2 In 2011, a total of 94.1% of
ESA-treated US hemodialysis patients used EPO and
5.9% used DPO.3 By contrast, DPO is much more
commonly used in other countries. For example, in
2011, DPO was used by 65.1% of hemodialysis pa-
tients inCanada, 55.2% inFrance, and 48.2% in Japan.3
While the ability of DPO to increase and maintain he-
moglobin concentrations is similar to that of EPO,4,5
sufﬁciently powered studies of the comparative safety
of DPO versus EPO are lacking.
The recent case of another ESA, peginesatide, that
was recalled less than a year after approval by the US
Food and Drug Administration due to high rates of
death and cardiovascular events not detected during
its relatively large phase 3 program6,7 casts doubt on
the validity of a “class effect” assumption of com-
parable safety among other ESAs. A recent meta-
analysis of randomized trials that assigned patients
with chronic kidney disease to DPO versus EPO
found no difference in mortality, but the upper bound
of the 95% conﬁdence interval (CI) exceeded a
doubling in risk (odds ratio, 1.33; 95% CI, 0.88-
2.01).8 A recent network meta-analysis that examined
additional (nondeath) outcomes, but included fewer
trials, concluded that any comparisons among ESAs
of cardiovascular outcomes such as myocardial
infarction (MI) or stroke were limited by high un-
certainty.9 Hence, we sought to compare the safety of
DPO and EPO in a large cohort of typical patients
with ESRD initiating maintenance hemodialysis
therapy. In this study, we exploited the natural
experiment that occurs when facilities make a for-
mulary decision to provide one or the other drug to all
or nearly all of its patients.
METHODS
Study Rationale
Dialysis facilities contract their medications through pre-
speciﬁed formularies, with a facility typically administrating either
DPO or EPO, but rarely both. We considered the choice between
DPO and EPO as potentially random relative to patient charac-
teristics because such decisions, particularly at the introduction of
a new drug, are primarily based on contracts with drug suppliers.
Because it is not expected that patients choose a facility based on
whether it uses DPO or EPO, we may have the opportunity to
exploit these facility-level decisions as a natural experiment.
Speciﬁcally, we used administrative data to mimic a cluster-
randomized design, with clustering based on facility by assign-
ing facilities and their incident hemodialysis patients to a treatment
arm based on the practice pattern of their facility. We then
matched facility pairs for analytic purposes.
Study Population: Patient Selection, Exposure Assignment,
and Follow-up
From the US Renal Data System (USRDS), the national
registry of persons with ESRD, we identiﬁed from billing codes toAm J Kidney Dis. 2015;66(1):106-113Medicare all ESA administrations in years 2003 to 2010. We then
deﬁned the proportion of ESA administrations that were for DPO
versus for EPO in each hemodialysis facility and calendar month.
For each facility, we termed a month a DPO facility-month
if $95% of administered ESAs in that facility and month were
DPO; correspondingly, if $95% of administrations were EPO, we
considered it an EPO facility-month. All other facility-months
were categorized as “mixed.” We restricted our study to inde-
pendent and hospital-based facilities because it has previously
been shown (and conﬁrmed here) that large dialysis chains almost
exclusively use EPO.2 Beginning with the approval of DPO by the
US Food and Drug Administration for the US market in 2001, we
identiﬁed all facility-level switches from EPO to DPO. Among the
facilities that almost exclusively administered EPO in the same
month and year, we randomly selected one facility matched on
geographic region (census division), proﬁt status (for proﬁt vs not
for proﬁt), and facility type (free-standing vs hospital based) as
reported in the USRDS. This algorithm was applied to all observed
facility switches from EPO to DPO.
From the ﬁrst day of the matching month onward, we identiﬁed
all patients regardless of insurance status who initiated hemodi-
alysis therapy in a DPO facility and its matched EPO facility
(inception cohort design). If a facility switched back from pre-
dominant DPO to predominant EPO use or its matching EPO fa-
cility switched to DPO, both matched facilities were no longer
eligible to contribute new incident patients to the study. Patients
initiating hemodialysis therapy in a DPO facility were assigned
DPO and patients initiating hemodialysis therapy in an EPO fa-
cility were assigned EPO as their respective exposures, regardless
of whether they actually received DPO, EPO, or no ESA. We used
this cohort to study mortality outcomes, which are recorded
regardless of payor. Patients were censored at the end of available
data (December 31, 2010), upon switching to peritoneal dialysis
therapy, upon receipt of a kidney transplant, when switching to
another hemodialysis facility, or when their facility or its match
switched to predominant use of the respective other ESA or was
acquired by a large dialysis chain.
For analyses of nonfatal outcomes, we relied on claims-based
data. Therefore, we restricted the cohort to patients who survived
90 days after the initiation of dialysis therapy and who had Medi-
care Parts A 1 B as their primary payor on that day. In the United
States, most patients with ESRD are eligible for Medicare beneﬁts
after a 90-day waiting period from the date of ESRD incidence
certiﬁed to the Centers for Medicare &Medicaid Services (CMS) in
the Medical Evidence Report (form CMS-2728). Patients were
followed up from day 91 after initiation of hemodialysis therapy
until censoring for the reasons listed, as well as death (for nonfatal
outcomes) or loss of Medicare Parts A 1 B coverage.
To examine the validity of using facility preference as the proxy
for true exposure over time, we plotted for each month of follow-
up the percentages of actual ESA received for each exposure group
among prevalent and incident patients who had Medicare Parts
A 1 B.
Patient Characteristics
From the USRDS patient ﬁle, we ascertained patients’ age, sex,
race (white, black, Asian, Native American/Paciﬁc Islander, and
other), ethnicity (Hispanic vs non-Hispanic), and whether they
were covered by Medicaid (a health insurance program for low-
income patients). From the Medical Evidence Report, we ascer-
tained the reported presence of several comorbid conditions
(diabetes, hypertension, arteriosclerotic heart disease, heart failure,
peripheral artery disease, cerebrovascular disease, chronic
obstructive lung disease, cancer, inability to ambulate or transfer,
tobacco use, drug use, and alcohol use), as well as body mass
index, serum hemoglobin and serum albumin concentrations, and
the reported estimated glomerular ﬁltration rate at initiation of107
Table 1. Characteristics of DPO and Matched EPO Facilities
Variable DPO (n 5 492) EPO (n 5 492)
Facility type
Free-standing 173 (35.2) 173 (35.2)
Hospital 319 (64.8) 319 (64.8)
Profit status
Not for profit 359 (73.0) 359 (73.0)
For profit 133 (27.0) 133 (27.0)
Facility size
0-49 patients 240 (48.8) 260 (52.8)
50-99 patients 148 (30.1) 133 (27.0)
$100 patients 104 (21.1) 99 (20.1)
Region
Northwest 102 (20.7) 102 (20.7)
Midwest 215 (43.7) 215 (43.7)
South 106 (21.5) 106 (21.5)
West 69 (14.0) 69 (14.0)
Note: Values are given as number (percentage). From among
508 facilities that switched from EPO to DPO between 2003 and
2010, we hard-matched 1 dialysis unit that remained with EPO
on facility type (hospital based vs independent), for-profit status,
and geographic region in the month and year of the switching
event. We were able to match 492 (96.9%) facilities that
switched to DPO.
Abbreviations: DPO, darbepoetin alfa; EPO, epoetin alfa.
Winkelmayer et aldialysis therapy. We also noted whether a patient was reported in
the Medical Evidence Report to have received ESAs prior to
initiation of dialysis therapy.
Outcomes
Mortality from any cause and cardiovascular mortality were
ascertained from the death ﬁle in the USRDS, which collates
pertinent information from several federal sources. Nonfatal out-
comes of interest were ascertained from International Classiﬁca-
tion of Diseases, Ninth Revision (ICD-9) diagnosis codes (primary
diagnosis ﬁeld) from inpatient Medicare claims using validated
algorithms and included stroke (ICD-9 codes 430, 431, 432.x,
433.x1, 434.x1, 436, and 437.1), MI (ICD-9 code 410.x1), and a
composite of stroke, MI, and cardiovascular mortality.10
Statistical Analysis
We ﬁrst tabulated characteristics of the matched DPO and EPO
facilities. We then tabulated characteristics of all enrolled incident
hemodialysis patients by whether they dialyzed in a DPO versus
an EPO facility. Groups were compared using standardized dif-
ference, with ,10% indicating good balance.11 We examined
cumulative incidence plots for all outcomes for any differences in
event rates or censoring events. We used Cox proportional hazards
regression stratiﬁed on facility pair to estimate unadjusted hazard
ratios (HRs) and corresponding 95% CIs. Schoenfeld residual
plots were examined to identify any violations of the proportion-
ality assumption. Because a few characteristics were slightly un-
balanced between groups, we also ﬁt demographics-adjusted
models and models that included all reported comorbid conditions
and biometric/laboratory characteristics. Missing data were
addressed using the MICE (Multivariate Imputation by Chai-
ned Equations) package in R statistical software (version 3.0; R
Foundation for Statistical Computing).12 Results from complete
case analyses did not differ and are only reported in Table S1. We
also conducted a set of analyses that were restricted to patients who
were reported, per Medical Evidence Report, to have not received
an ESA prior to ESRD (ESA naive). We also inspected cumulative
incident plots of all outcomes and censoring events and conﬁrmed
in formal competing-risk analyses that reported results were un-
affected by potential informative censoring (data not shown).
We conducted statistical analyses using SAS software, version 9.3
(SAS Institute Inc) andR statistical software. The StanfordUniversity
School of Medicine Institutional Review Board approved the study.
RESULTS
From 2003 through 2010, of 5,872 US hemodial-
ysis facilities, 2,067 (35.2%) were not part of a chain
and of those, 508 (24.6%) facilities switched from
EPO to DPO (see Fig S1, available as online sup-
plementary material, for the timing of these switches).
Of those, we matched on center type, proﬁt status, and
geographic region 492 units (96.9%) with 1 unit each
that had continued to use EPO in the same month and
year (Table 1). After the index date and prior to
censoring of the matched facility-pair, 19,932 patients
initiated hemodialysis therapy in these centers, 9,465
(47.5%) in DPO and 10,467 (52.5%) in EPO facilities
(Fig 1), and were followed up for a total of 21,848
person-years. We locked the analytical data set on
October 18, 2013, prior to examining outcomes and
conducted power calculations for fatal and nonfatal
end points, which demonstrated excellent power for
the detection of even small effect sizes (Fig S2). For108example, we had 98% and 53% power to detect 10%
or 5% increases in mortality, respectively.
Patient characteristics were similar among patients
initiating hemodialysis therapy in DPO versus EPO
facilities with the exception of race and ethnicity
(Table 2): DPO facilities had fewer Hispanic and
Asian patients and also had slightly lower reported
serum albumin concentrations. Patient-level separa-
tion of ESA exposure during follow-up, assessed from
monthly prevalent patients with Medicare coverage in
these units, was excellent, as shown in Fig 2.
Furthermore, use of intravenous iron and achieved
hemoglobin concentrations during follow-up were
similar (Figs S3 and S4). Cumulative incidence plots
did not indicate differential censoring between the
exposure groups and competing-risk analyses yielded
essentially identical results (data not shown).
During follow-up, 5,550 deaths and 2,037 cardio-
vascular deaths occurred for incidence rates of 253.2
and 92.9 per 1,000 person-years, respectively
(Table 3). Compared with patients who initiated
dialysis therapy in EPO facilities, patients in DPO
facilities had 12% higher mortality (HR, 1.12; 95%
CI, 1.06-1.20), but survival did not differ signiﬁcantly
between groups after adjustment for demographic
characteristics (HR, 1.06; 95% CI, 1.00-1.13) or
adjustment for all recorded factors (HR, 1.05; 95%
CI, 0.99-1.12). Results for cardiovascular mortality
were very similar, albeit with wider conﬁdence limits
(adjusted HR, 1.05; 95% CI, 0.94-1.16; Table 3).Am J Kidney Dis. 2015;66(1):106-113
Figure 1. Numbers of facilities
matched and incident patients enrolled.
Whether a patient was erythropoiesis-
stimulating agent (ESA) naive was
determined from the Medical Evidence
Report. Abbreviations: DPO, darbe-
poetin alfa; EPO, epoetin alfa; ESRD,
end-stage renal disease.
Darbepoetin Versus Epoetin in HemodialysisFor analyses of nonfatal end points that were
ascertained from medical claims, we identiﬁed 9,455
incident hemodialysis patients who were alive and
covered by Medicare Parts A 1 B at 90 days after the
reported ESRD date; 4,542 (48.0%) in DPO and 4,913
(52.0%) in EPO facilities. The few imbalances between
groups mirrored those of the larger cohort described
(Table S2). During 10,457 and 10,363 person-years,
248 strokes, and 372 MIs were recorded for inci-
dence rates of 23.7 and 35.9 per 1,000 person-years,
respectively. We found no differences in adjusted
stroke or MI rates or their composite with cardiovas-
cular death (HR, 1.10; 95% CI, 0.96-1.25; Table 3).
In subgroup analyses of 11,553 patients who were
reported to have been ESA-naive at hemodialysis
therapy initiation, results for mortality (HR, 1.01; 95%
CI, 0.92-1.10) and cardiovascular mortality (HR, 1.01;
95% CI, 0.87-1.17) were consistent with those ob-
tained from the full cohort (Table S3). Similarly, in the
subset of 5,474 patients who were ESA naive, alive,
and with Medicare coverage at day 90, nonfatal stroke,
nonfatal MI, and their composite with cardiovascular
mortality were not associated with DPO versus EPO in
adjusted analyses (HR, 1.13; 95% CI, 0.95-1.35).
DISCUSSION
DPO and EPO are 2 medications from the ESA
class that are commonly used for the treatment ofAm J Kidney Dis. 2015;66(1):106-113anemia in individuals receiving dialysis and in other
settings. Although similar in their ability to increase
and maintain hemoglobin concentrations in short-term
studies,4,5,13 longer-term clinical trials that could
detect meaningful differences in adverse outcomes are
absent. In a meta-analysis of head-to-head trials of
DPO versus EPO, no signiﬁcant difference in mor-
tality was found, but numbers were small, follow-up
was short, and CIs were wide and compatible with
sizeable excess mortality in patients randomly
assigned to DPO.8 In this study, we leveraged the
apparent natural experiment that occurred when fa-
cilities switched from EPO to DPO to compare out-
comes in patients on hemodialysis therapy.
Importantly, we detected no signiﬁcant differences in
death, cardiovascular death, or nonfatal cardiovascu-
lar events between patients treated in DPO versus
EPO facilities.
We focused on cardiovascular and mortality end
points because previous randomized trials of either
DPO or EPO that either compared higher versus lower
hemoglobin targets or active ESA versus placebo had
identiﬁed mostly cardiovascular safety signals. How-
ever, the speciﬁc safety signals differed across studies,
which raises the possibility that the type of adverse
outcome depended on the speciﬁc ESA used.14 As
already stated in our meta-analysis,8 there are well-
documented biological differences between DPO and109
Table 2. Characteristics of Patients Initiating Dialysis in Matched DPO and EPO Facilities
Variable All Patients DPO EPO Stand Diff
No. of patients 19,932 (100.0) 9,465 (47.5) 10,467 (52.5)
Age (y) 65 [53-75] 65 [54-76] 64 [53-75] 6.2
Female sex 8,808 (44.2) 4,159 (43.9) 4,649 (44.4) 21.0
Racea
White 13,515 (67.8) 6,599 (69.7) 6,916 (66.1) 7.8
Black 5,188 (26.0) 2,385 (25.2) 2,803 (26.8) 23.6
Asian 783 (3.9) 260 (2.7) 523 (5.0) 211.7
Other 422 (2.1) 212 (2.2) 210 (2.0) 1.6
Hispanic ethnicitya 2,410 (12.1) 910 (9.6) 1,500 (14.3) 214.7
Medicaid eligibility 5,297 (26.6) 2,477 (26.2) 2,820 (26.9) 21.9
Received ESA prior to ESRD 5,807 (29.1) 2,731 (28.9) 3,076 (29.4) 21.6
Comorbid conditions
Diabetes 10,710 (53.7) 52,00 (54.9) 5,510 (52.6) 4.5
Hypertension 16,923 (84.9) 8,157 (86.2) 8,766 (83.7) 6.5
Arteriosclerotic heart disease 5,548 (27.8) 2,627 (27.8) 2,921 (27.9) 20.4
Heart failure 7,184 (36.0) 3,453 (36.5) 3,731 (35.6) 1.6
Peripheral vascular disease 3,231 (16.2) 1,558 (16.5) 1,673 (16.0) 1.2
Cerebrovascular disease 2,238 (11.2) 1,075 (11.4) 1,163 (11.1) 0.7
Chronic obstructive lung disease 2,273 (11.4) 1,223 (12.9) 1,050 (10.0) 9.0
Cancer 1,558 (7.8) 841 (8.9) 717 (6.9) 7.5
Unable to ambulate or transfer 1,784 (9.0) 861 (9.1) 923 (8.8) 0.9
Tobacco use 1,422 (7.1) 707 (7.5) 715 (6.8) 2.4
Drug use 422 (2.1) 199 (2.1) 223 (2.1) 20.2
Alcohol use 384 (1.9) 169 (1.8) 215 (2.1) 22.0
Reported measurements
BMI (kg/m2)a 27.3 [23.4-32.8] 27.5 [23.5-33.1] 27.1 [23.3-32.5] 5.7
Hemoglobin (g/dL)a 9.9 [8.8-11.0] 9.9 [8.9-11.0] 9.8 [8.8-10.9] 6.8
Serum albumin (g/dL)a 3.2 [2.7-3.6] 3.1 [2.6-3.6] 3.2 [2.7-3.6] 10.5
eGFR at dialysis initiation (mL/min/1.73 m2)a 9.9 [7.2-13.3] 9.7 [7.0-13.1] 10.1 [7.5-13.4] 8.2
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as median [interquartile
range]. All incident hemodialysis patients in these facilities were captured for analysis of mortality end points regardless of health
insurance status.
Abbreviations: BMI, body mass index; DPO, darbepoetin alfa; eGFR, estimated glomerular filtration rate; EPO, epoetin alfa; ESA,
erythropoiesis-stimulating agent; ESRD, end-stage renal disease; Stand Diff, standardized difference.
aPercentages of the missing relevant variable are as follows: race, 0.1%; Hispanic ethnicity, 0.6%; BMI, 1.9%; hemoglobin level,
9.1%; albumin level, 20.0%; eGFR at dialysis therapy initiation, 2.3%.
Winkelmayer et alEPO, with the most important difference for the
clinician being the prolonged half-life and increased
biological activity for DPO in comparison to EPO.15-18
Although the therapeutic aim of ESA treatment is to
increase or maintain hemoglobin concentrations in
patients with anemia, other effects on additional tis-
sues and organs have been identiﬁed, including the
brain, heart, uterus, and kidney.19,20 Erythropoietin
may possess pleiotropic properties, stimulating pro-
liferation, chemotaxis, and angiogenesis while down-
regulating apoptosis.21,22 It appears to be an important
regulator of vascular repair and may also be involved
in neoangiogenesis. Both DPO and EPO have been
shown to enhance mobilization of bone marrow–
derived endothelial-progenitor cells in humans23,24;
these cells play important roles in vascular repair and
endothelial regeneration in ischemia-reperfusion
injury.20,25,26 However, these nonhematopoietic ef-
fects of ESAs may differ from and be disproportional110to their relative effectiveness in inducing hematopoi-
esis. Another derivative of erythropoietin, carbamy-
lated erythropoietin, has been shown to offer similar
cardioprotection as epoetin alfa in an animal model
while not exerting an effect on hematocrit.27,28 This
experimental research then raises the important ques-
tion that we tried to address in this study, namely
whether off-target nonhematopoietic effects may differ
between DPO and EPO.
Certain limitations of our study require consider-
ation. Our comparison of DPO and EPO was not ran-
domized and therefore residual confounding remains
possible. However, we used an intuitive quasi-
experimental approach that mimicked a cluster-
randomized trial in which facilities rather than
individual patients are randomly assigned to receiving
one treatment or another. Although the current study
was not randomized, treatment with DPO versus EPO
was presumably determined by formulary decisions onAm J Kidney Dis. 2015;66(1):106-113
Figure 2. Actual treatment received
for patients in darbepoetin alfa (DPO)
versus epoetin alfa (EPO) facilities, by
month of follow-up. (Upper panels)
Percentages of prevalent hemodialysis
patients with Medicare Parts A 1 B
who received DPO versus EPO versus
both in each calendar month. (Lower
panels) Percentages of incident hemo-
dialysis patients with Medicare Parts
A 1 B who received DPO versus EPO
versus both in each calendar month
(corresponds to analyses of nonfatal
outcomes). Left panels, DPO facilities;
right panels, EPO facilities.
Darbepoetin Versus Epoetin in Hemodialysisthe facility level and was found to be mostly inde-
pendent of patient characteristics. After matching fa-
cilities by speciﬁc criteria such as location, type, and
proﬁt status, patients were similar between facilities
that had switched to DPO and EPO. Achieved hemo-
globin concentrations and use of intravenous iron over
the full range of follow-up were similar between the 2
groups, corroborating that the only difference in ane-
mia management was the choice of ESA, but not a
presumed or explicit hemoglobin target or iron use
strategy. However, we cannot ﬁrmly establish from
data available to us that facility switches were a
consequence of facility-wide formulary decisions;
alternatively, these switches could have been caused
by clinician preferences, nursing workloads, or con-
cerns about EPO safety and could have been correlated
with other facility practices (eg, dialysis prescriptionsTable 3. Follow-up Time, Number of Events, Incidence Rates, and
Darbepoetin Alfa Ver
Outcomes
Sample
Size
F/U Time
(person-y)
No. of
Events
Incidenc
(per 1,000 p
Mortality 19,932 21,917.67 5,550 253.
Cardiovascular mortality 19,932 21,917.67 2,037 92.
Stroke 9,455 10,456.87 248 23.
Myocardial infarction 9,455 10,363.29 372 35.
Compositea 9,455 10,190.52 1,424 139.
Note: Time-to-event analyses started on the day of reported inciden
91 after end-stage renal disease for nonfatal and composite outco
Medicaid eligibility, and incidence year. Model 2 additionally adjuste
concentration, and estimated glomerular filtration rate. Multiple impu
case analyses were not materially different (see Table S2).
Abbreviation: F/U, follow up.
aComposite of stroke, myocardial infarction, and cardiovascular m
Am J Kidney Dis. 2015;66(1):106-113and infection control protocols) that may have
confounded the estimated associations.
A second limitation comes from the fact that DPO
is not widely used in the United States, which
required that we restrict our analyses to nonchain free-
standing and hospital-based facilities. Whether our
results generalize to other health care settings such as
chain dialysis facilities or to other countries is un-
known. Although the ensuing sample size was rela-
tively modest for a national registry analysis, it was
more than 20 times the sample size of all randomized
trials of DPO versus EPO combined (and whose end
points were hemoglobin control), which enabled us to
study important outcomes with excellent power. We
were also able to demonstrate that there was very little
exposure misclassiﬁcation, with an average 98.9% of
ESA recipients in DPO facilities receiving DPO andHazard Ratios; Incident Patients in Hemodialysis Centers Using
sus Epoetin Alfa
Hazard Ratio (95% Confidence Interval)
e Rate
erson-y) Unadjusted Model 1 Model 2
22 1.12 (1.06-1.20) 1.06 (1.00-1.13) 1.05 (0.99-1.12)
94 1.11 (1.00-1.24) 1.05 (0.94-1.16) 1.05 (0.94-1.16)
72 0.98 (0.72-1.34) 1.04 (0.76-1.43) 1.02 (0.75-1.41)
90 1.17 (0.91-1.50) 1.17 (0.91-1.50) 1.16 (0.90-1.50)
74 1.10 (0.97-1.25) 1.09 (0.96-1.24) 1.10 (0.96-1.25)
ce of end-stage renal disease for mortality outcomes and on day
mes. Model 1 adjusted for age, sex, race, Hispanic ethnicity,
d for all comorbid conditions, body mass index, serum albumin
tation was used to address missing data. Results from complete
ortality.
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Winkelmayer et al99.7% of ESA recipients in EPO facilities receiving
EPO throughout follow-up. Thus, statistical power
was not diluted by treatment crossovers. However,
not all patients received ESA and not all patients who
did received it throughout follow-up, and thus a per-
protocol analysis of patients treated with ESA
would not possess this inherent bias toward the null.
Unfortunately, the speciﬁc question asked in our
study is not addressable by using causal methods (eg,
marginal structural models) developed to address
time-dependent confounding (and our data set would
not have provided the highly granular data required to
support the use of such methods). Our sensitivity
analyses of presumably ESA-naive patients used in-
formation provided on the Medical Evidence Report,
which has been shown to substantially misclassify
pre-ESRD use of ESAs in 2 validation studies.29,30
Finally, we were unable to study other ESAs,
including epoetin beta, epoetin delta, epoetin omega,
biosimilar epoetins, or the long-acting methoxy
polyethylene glycol–epoetin beta, all of which are
available in other countries, but not currently used in
the United States due to patent restrictions.
We conclude that DPO and EPO possess approxi-
mately similar safety proﬁles, at least within the he-
modialysis setting, with regard to cardiovascular and
mortality outcomes, although small excess risks from
DPO cannot be ruled out.
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